Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes

被引:17
|
作者
El-Ashmawy, Hazem M. [1 ]
Ahmed, Azza M. [2 ]
机构
[1] Zagazig Univ, Fac Med, Dept Internal Med, Zagazig, Egypt
[2] Zagazig Univ, Fac Med, Dept Clin Pathol, Zagazig, Egypt
关键词
fetuin-B; nonalcoholic fatty liver disease; type 2 diabetes mellitus; C-REACTIVE PROTEIN; INSULIN-RESISTANCE; METABOLIC SYNDROME; A LEVELS; RISK; ATHEROSCLEROSIS; STEATOHEPATITIS; INFLAMMATION; ASSOCIATION; GLUCOSE;
D O I
10.1097/MEG.0000000000001354
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective Previous studies have assessed serum fetuin-B and its relation to nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) and as a link between them through inducing insulin resistance (IR). Therefore, we examined the potential of serum fetuin-B to be an independent marker for NAFLD in patients with T2DM. Patients and methods The study group consisted of 270 patients with T2DM. Clinical and laboratory features were evaluated. The NAFLD severity was graded by ultrasound into three subgroups: grade 0 (no fatty liver), grade 1 (mild fatty liver), and grade 2-3 (medium to severe fatty liver). Fetuin-B, retinol-binding protein-4, and adiponectin were measured. Results Patients with grade 2-3 NAFLD had high fetuin-B levels in comparison with non-NAFLD group. Age and sex adjusted fetuin-B demonstrated positive correlations with triglycerides, gamma-glutamyl transferase, fasting plasma glucose, 2-h postprandial plasma glucose, homeostasis model assessment of IR, fasting insulin, glycated hemoglobin, high-sensitivity C-reactive protein, and estimated glomerular filtration rate, but it had a negative correlation with serum creatinine. Adiponectin level was decreased with increasing NAFLD severity, but no difference was found in retinol-binding protein-4. The estimated odds ratio (OR) for the occurrence of grade 2-3 NAFLD was increased significantly with increasing levels of fetuin-B (OR: 3.92; 95% confidence interval: 2.14-8.32 vs. OR: 8.91; 95% confidence interval: 4.22-18.41). The OR of fetuin-B in the uppermost tertile group was still significant after controlling for homeostasis model assessment of IR, glycated hemoglobin, waist circumference, BMI, hepatic enzymes, high-density lipoprotein cholesterol, triglycerides, and high-sensitivity C-reactive protein. Conclusions Our study demonstrated that serum fetuin-B had an independent association with NAFLD in patients with T2DM.
引用
收藏
页码:859 / 864
页数:6
相关论文
共 50 条
  • [21] Nonalcoholic fatty liver disease in type 2 diabetes mellitus
    Cusi, Kenneth
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2009, 16 (02) : 141 - 149
  • [22] Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Wu, Haiya
    Jia, Weiping
    Bao, Yuqian
    Lu, Junxi
    Zhu, Jiehua
    Wang, Ren
    Chen, Yaqing
    Xiang, Kunsan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 (02) : 185 - 190
  • [23] Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease
    Raschi, Emanuel
    Mazzotti, Arianna
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    Marchesini, Giulio
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (17) : 1903 - 1914
  • [24] Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
    Pennisi, G.
    Enea, M.
    Falco, V.
    Aithal, G. P.
    Palaniyappan, N.
    Yilmaz, Y.
    Boursier, J.
    Cassinotto, C.
    De Ledinghen, V.
    Chan, W. K.
    Mahadeva, S.
    Eddowes, P.
    Newsome, P.
    Karlas, T.
    Wiegand, J.
    Wong, V. Wai-Sun
    Schattenberg, J. M.
    Labenz, C.
    Kim, W.
    Lee, M. S.
    Lupsor-Platon, M.
    Cobbold, J. F. L.
    Fan, J.
    Shen, F.
    Staufer, K.
    Trauner, M.
    Stauber, R.
    Nakajima, A.
    Yoneda, M.
    Bugianesi, E.
    Younes, R.
    Gaia, S.
    Zheng, M.
    Camma, C.
    Anstee, Q. M.
    Mozes, F. E.
    Pavlides, M.
    Petta, S.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S12 - S13
  • [25] Hepatokines Fetuin-A and Fetuin-B status in obese Saudi patient with diabetes mellitus type 2
    Almarashda, Ola
    Abdi, Saba
    Yakout, Sobhy
    Khattak, Malak Nawaz Khan
    Al-Daghri, Nasser M.
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (05): : 3292 - 3302
  • [26] Fetuin A is a Predictor of Liver Fat in Preoperative Patients with Nonalcoholic Fatty Liver Disease
    von Loeffelholz, C.
    Horn, P.
    Birkenfeld, A. L.
    Claus, R. A.
    Metzing, B. U.
    Doecke, S.
    Jahreis, G.
    Heller, R.
    Hoppe, S.
    Stockmann, M.
    Lock, J. F.
    Rieger, A.
    Weickert, M. O.
    Settmacher, U.
    Rauchfuss, F.
    Pfeiffer, A. F. H.
    Bauer, M.
    Sponholz, C.
    JOURNAL OF INVESTIGATIVE SURGERY, 2016, 29 (05) : 266 - 274
  • [27] Serum Fetuin-A Concentrations in Subjects With Prediabetes and Nonalcoholic Fatty Liver Disease
    Ou, Horng-Yih
    Yang, Yih-Ching
    Wu, Hung-Tsung
    Wu, Jin-Shang
    Lu, Feng-Hwa
    Chang, Chih-Jen
    DIABETES, 2012, 61 : A691 - A691
  • [28] The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    Dai, Chia-Yen
    Fang, Tzu-Jung
    Hung, Wei-Wen
    Tsai, Hui-Ju
    Tsai, Yi-Chun
    BIOMEDICINES, 2022, 10 (07)
  • [29] Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Are Mutually Independent Predictors of Cardiovascular Events in Patients with Established Cardiovascular Disease
    Saely, Christoph H.
    Vonbank, Alexander
    Maechler, Maximilian
    Larcher, Barbara
    Sprenger, Lukas
    Mader, Arthur
    Purin, Daniela
    Klement, Margaretha
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    DIABETES, 2020, 69
  • [30] Improvement of Lipi Huatan Quyu Decoction on Chronic Inflammatory State of Type 2 Diabetes Mellitus Patients with Non-Alcoholic Fatty Liver Disease and Its Effect on Serum Levels of Fetuin-B and Chemerin
    Pu, Yongli
    Zhang, Yonghui
    Li, Yonghua
    Liu, Feng
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 127 : 15 - 15